ReviewNeuropharmacology2013
Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.
Review in Neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- The Causal Relationship Between Palmitoylation Genes and Parkinson's Disease: A Mendelian Randomization Study.Journal of molecular neuroscience : MN · 2025Article
- Psychosis Caused by a Somatic Condition: How to Make the Diagnosis? A Systematic Literature Review.Children (Basel, Switzerland) · 2023Review
- Altered cortical thickness development in 22q11.2 deletion syndrome and association with psychotic symptoms.Molecular psychiatry · 2021Article
- Patterns of Cortical Folding Associated with Autistic Symptoms in Carriers and Noncarriers of the 22q11.2 Microdeletion.Cerebral cortex (New York, N.Y. : 1991) · 2020Article
- Neuroanatomical underpinnings of autism symptomatology in carriers and non-carriers of the 22q11.2 microdeletion.Molecular autism · 2020Article
- The Neuroanatomy of Autism Spectrum Disorder Symptomatology in 22q11.2 Deletion Syndrome.Cerebral cortex (New York, N.Y. : 1991) · 2019Article
- Olfactory deficits and psychosis-spectrum symptoms in 22q11.2 deletion syndrome.Schizophrenia research · 2018Article
- The SERCA2: A Gatekeeper of Neuronal Calcium Homeostasis in the Brain.Cellular and molecular neurobiology · 2018Review
- Emergent, remitted and persistent psychosis-spectrum symptoms in 22q11.2 deletion syndrome.Translational psychiatry · 2017Article
- Intrinsic Connectivity Network-Based Classification and Detection of Psychotic Symptoms in Youth With 22q11.2 Deletions.Cerebral cortex (New York, N.Y. : 1991) · 2017Article
- Atypical functional connectivity in resting-state networks of individuals with 22q11.2 deletion syndrome: associations with neurocognitive and psychiatric functioning.Journal of neurodevelopmental disorders · 2016Article
- An affected core drives network integration deficits of the structural connectome in 22q11.2 deletion syndrome.NeuroImage. Clinical · 2016Article
- Default mode network connectivity and reciprocal social behavior in 22q11.2 deletion syndrome.Social cognitive and affective neuroscience · 2014Article
- Subthreshold psychotic symptoms in 22q11.2 deletion syndrome.Journal of the American Academy of Child and Adolescent Psychiatry · 2014Article
- Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated.Psychological medicine · 2014Article
- Ohnologs are overrepresented in pathogenic copy number mutations.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- MicroRNAs as the cause of schizophrenia in 22q11.2 deletion carriers, and possible implications for idiopathic disease: a mini-review.Frontiers in molecular neuroscience · 2013Review
- 22q11 deletion syndrome: a review of the neuropsychiatric features and their neurobiological basis.Neuropsychiatric disease and treatment · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Schizophrenia is a devastating neurodevelopmental disorder that, despite extensive research, still poses a considerable challenge to attempts to unravel its heterogeneity, and the complex biochemical mechanisms by which it arises. While the majority of cases are of unknown etiology, accumulating evidence suggests that rare genetic mutations, such as 22q11.2 Deletion Syndrome (22qDS), can play a significant role in predisposition to the illness. Up to 25% of individuals with 22qDS eventually develop schizophrenia; conversely, this deletion is estimated to account for 1-2% of schizophrenia cases overall. This locus of Chromosome 22q11.2 contains genes that encode for proteins and enzymes involved in regulating neurotransmission, neuronal development, myelination, microRNA processing, and post-translational protein modifications. As a consequence of the deletion, affected individuals exhibit cognitive dysfunction, structural and functional brain abnormalities, and neurodevelopmental anomalies that parallel many of the phenotypic characteristics of schizophrenia. As an illustration of the value of rare, highly penetrant genetic subtypes for elucidating pathological mechanisms of complex neuropsychiatric disorders, we provide here an overview of the cellular, network, and systems-level anomalies found in 22qDS, and review the intriguing evidence for this disorder's association with schizophrenia. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.